Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JYP0322 in ROS1-positive NSCLC after ROS1-TKI failure
NCT07154368Phase 3Not yet recruiting
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Sep 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of JYP0322 in non-small cell lung cancer (NSCLC), sponsored by Guangzhou JOYO Pharma. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
JYP0322
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07154368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07154368.